Cargando…

1184. Activity of anti-pseudomonal antibiotics among all Pseudomonas aeruginosa (PSA) at an academic medical health system, including β-lactam, multi-drug (MDR) and extensively drug resistant (XDR) strains

BACKGROUND: PSA with MDR and XDR are a growing threat, and appropriate initial treatment of this organism is critical. C/T is a novel antibiotic with broad gram-negative in vitro susceptibility among surveillance studies. However comprehensive susceptibility analyses of C/T among PSA clinical isolat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rose, Warren, Heikkinen, Benjamin, Radaatz, Janet, Puzniak, Laura A, Dillon, Ryan J, Schulz, Lucas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776131/ http://dx.doi.org/10.1093/ofid/ofaa439.1370

Ejemplares similares

Outcomes of adult patients in the intensive care unit with Pseudomonas aeruginosa pneumonia who received an active anti‐pseudomonal β‐lactam: Does “S” equal success in the presence of resistance to other anti‐pseudomonal β‐lactams?
por: Lodise, Thomas P., et al.
Publicado: (2021)

De-Escalating Anti-Pseudomonal β-Lactams
por: Catteeuw, J, et al.
Publicado: (2015)

MDR & XDR Tuberculosis
por: Kumar, Prahlad
Publicado: (2017)

Analysing non-synonymous mutations in XDR and MDR tuberculosis drugs
por: Surana, Pallavi, et al.
Publicado: (2019)

Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa
por: Kothari, Ashish, et al.
Publicado: (2023)

1623. Outcomes of Critically Ill Adults, Hospitalized Patients (Pts) with Pseudomonas aeruginosa (PSA) Hospital- and Ventilator-Associated Pneumonia (HAP/VAP) Who Received an Active Anti-Pseudomonal β-Lactam (ASPB): Does “S” Equal Success in the Presence of Resistance to other ASPB?
por: Lodise, Thomas, et al.
Publicado: (2020)

Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB
por: Metcalfe, John, et al.
Publicado: (2019)

Transmission of MDR and XDR Tuberculosis in Shanghai, China
por: Zhao, Ming, et al.
Publicado: (2009)

Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran
por: Mirzaei, Bahman, et al.
Publicado: (2020)

Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains
por: Hameed, H. M. Adnan, et al.
Publicado: (2018)

Activity of Semi-Synthetic Mulinanes against MDR, Pre-XDR, and XDR Strains of Mycobacterium tuberculosis
por: Martínez-González, María Alejandrina, et al.
Publicado: (2021)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
por: Codecasa, Luigi R., et al.
Publicado: (2017)

Classification of Mycobacterium tuberculosis DR, MDR,XDR Isolates and Identification of Signature MutationPattern of Drug Resistance
por: Prasanna, Akshatha, et al.
Publicado: (2019)

2270. Initial Treatment Selection Among Patients with Recurrent Pseudomonas aeruginosa (PSA) Infections (Infxs): Does Prior PSA Antibiotic Susceptibility Results Effect Subsequent Empiric Treatment Decisions?
por: Puzniak, Laura, et al.
Publicado: (2019)

2406. “Real-world” Treatment of Multidrug-Resistant (MDR) or Extensively Drug-Resistant (XDR) P. aeruginosa Infections With Ceftolozane/Tazobactam (C/T) vs. a Polymyxin or Aminoglycoside (Poly/AG)-based Regimen: A Multicenter Comparative Effectiveness Study
por: Pogue, Jason M, et al.
Publicado: (2018)

1596. Ceftolozane/tazobactam (Zerbaxa) for the Treatment of Pseudomonas aeruginosa (PSA) Bacteremia: A Systematic Literature Review (SLR)
por: Dillon, Ryan J, et al.
Publicado: (2020)

The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks
por: Sirgel, Frederick A., et al.
Publicado: (2013)

The Burden of MDR/XDR Tuberculosis in Coastal Plains Population of China
por: Yang, Xiujun, et al.
Publicado: (2015)

MDR and XDR typhoid fever-a threat for the current decade?
por: Pustake, Manas, et al.
Publicado: (2021)

1601. Evaluation of Synergy with β-Lactams Plus Aztreonam Against Pseudomonas aeruginosa (PSA)
por: O’Donnell, J Nicholas, et al.
Publicado: (2019)

Virulence factors and integrons are associated with MDR and XDR phenotypes in nosocomial strains of Pseudomonas aeruginosa in a Venezuelan university hospital
por: Rodulfo, Hectorina, et al.
Publicado: (2019)

2395. Mechanism-Based-Susceptibility Testing (MBST) Using Disc Diffusion Assays (DDA) to Guide Treatment of Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa (MDR-XDR-Pa) in a Cystic Fibrosis (CF) Lung Transplant Recipient; Are We Ready for Combination Therapy vs. MDR-XDR-Pa?
por: Abbo, Lilian M, et al.
Publicado: (2018)

Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks
por: Sirgel, Frederick A., et al.
Publicado: (2015)

Linezolid-Associated Neuropathy in Patients with MDR/XDR Tuberculosis in Shenzhen, China
por: Zhang, Peize, et al.
Publicado: (2022)

Clinical Outcomes With Extended Versus Intermittent Infusion of Anti-Pseudomonal Beta-Lactams in Patients With Gram-Negative Bacteremia
por: Tran, Nikki N, et al.
Publicado: (2023)

Epidemic Levels of Drug Resistant Tuberculosis (MDR and XDR-TB) in a High HIV Prevalence Setting in Khayelitsha, South Africa
por: Cox, Helen S., et al.
Publicado: (2010)

1184. Investigating the Relationship Between Beta-Lactam Antibiotics and Thrombocytopenia: A Propensity Score-Matched Cohort Study
por: Chen, Alyssa Y, et al.
Publicado: (2023)

Risk Factors for MDR and XDR-TB in a Tertiary Referral Hospital in India
por: Balaji, V., et al.
Publicado: (2010)

Rapid diagnosis of MDR and XDR tuberculosis with the MeltPro TB assay in China
por: Pang, Yu, et al.
Publicado: (2016)

The Role of Adjunctive Therapies in Septic Shock by Gram Negative MDR/XDR Infections
por: Busani, Stefano, et al.
Publicado: (2017)

Correction to: Clinical Outcomes With Extended Versus Intermittent Infusion of Anti-Pseudomonal Beta-Lactams in Patients With Gram-Negative Bacteremia
Publicado: (2023)

ATP Bioluminescence Assay To Evaluate Antibiotic Combinations against Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa
por: Puig-Collderram, Berta, et al.
Publicado: (2022)

Development and Evaluation of Bacteriophage Cocktail to Eradicate Biofilms Formed by an Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa
por: Vashisth, Medhavi, et al.
Publicado: (2023)

COLLABORATION AGREEMENT No. K1184
por: The European Organisation for Nuclear Research, CERN, et al.
Publicado: (2005)

Emerging Trends of Multidrug-Resistant (MDR) and Extensively Drug-Resistant (XDR) Salmonella Typhi in a Tertiary Care Hospital of Lahore, Pakistan
por: Zakir, Muhammad, et al.
Publicado: (2021)

Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now
por: Chowdhury, Kona, et al.
Publicado: (2023)

Successful treatment of an extensively drug-resistant pseudomonal ulcer associated with contaminated artificial tears
por: Rezaei, Sina, et al.
Publicado: (2023)

Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence
por: Garg, Suneel Kumar, et al.
Publicado: (2017)

Effectiveness and Nephrotoxicity of Intravenous Polymyxin B in Chinese Patients With MDR and XDR Nosocomial Pneumonia
por: Zeng, Huihui, et al.
Publicado: (2021)

Virulence factors in multidrug (MDR) and Pan-drug resistant (XDR) Pseudomonas aeruginosa: a cross-sectional study of isolates recovered from ocular infections in a high-incidence setting in southern India
por: Naik, Poonam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l171noar9ggkqsf63k0qmjn9dv